B18.0
Conditions
Interventions
Group 1: To collect data on the demographic and clinical profile and rate of liver-related clinical events of patients with chronic HDV infection receiving HDV treatment (with the exception of bulevir
Sponsors
MYR GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. HBsAg-positive, adult (=18 years) patients who have been diagnosed with chronic HDV infection according to current EASL/ AASLD treatment guidelines, confirmed by respective documentation in the patients’ medical records. 2. Patients who have provided written informed consent or non-opposition according to local requirements.
Exclusion criteria
Exclusion criteria: 1. The patient is eligible for the Product Registry MYR-Reg-02, as the patient receives treatment with bulevirtide. 2. The patient is currently participating in a clinical trial with experimental treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To collect data on the demographic and clinical profile of patients with chronic hepatitis delta virus infection (HDV infection) from patients receiving HDV treatment (except for bulevirtide, trade name HEPCLUDEX®) and from patients receiving no HDV treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| To collect data on the rate of liver-related clinical events in patients with chronic HDV infection receiving HDV treatment (except for bulevirtide, trade name HEPCLUDEX®) and receiving no HDV treatment. | — |
Countries
France, Germany
Contacts
Public ContactGilead Study Director
Gilead Sciences, Inc.
Outcome results
None listed